For help on how to get the results you want, see our search tips.
620 results
-
List item
Human medicine European public assessment report (EPAR): Pemazyre (updated)
pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021,
, 
, 
, Revision: 6, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Ogivri (updated)
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 12/12/2018,
, Revision: 10, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Vegzelma (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022,, , Revision: 4, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Tremelimumab AstraZeneca (updated)
Tremelimumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/02/2023,, Revision: 1, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Benlysta (updated)
belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011,, Revision: 31, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Hulio (updated)
adalimumab, Hidradenitis Suppurativa; Psoriasis; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
Date of authorisation: 17/09/2018,, Revision: 15, Authorised, Last updated: 08/09/2023
-
List item
Human medicine European public assessment report (EPAR): Natpar (updated)
parathyroid hormone, Hypoparathyroidism
Date of authorisation: 24/04/2017,, , , Revision: 16, Authorised, Last updated: 08/09/2023
-
List item
Human medicine European public assessment report (EPAR): Emgality (updated)
Galcanezumab, Migraine Disorders
Date of authorisation: 14/11/2018,, Revision: 10, Authorised, Last updated: 07/09/2023
-
List item
Human medicine European public assessment report (EPAR): Nepexto (updated)
etanercept, Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Arthritis, Psoriatic; Spondylarthropathies; Spondylitis, Ankylosing; Psoriasis
Date of authorisation: 20/05/2020,, , Revision: 10, Authorised, Last updated: 07/09/2023
-
List item
Human medicine European public assessment report (EPAR): Voxzogo (updated)
Vosoritide, Achondroplasia
Date of authorisation: 26/08/2021,, , Revision: 3, Authorised, Last updated: 06/09/2023
-
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, , , Revision: 16, Authorised, Last updated: 05/09/2023
-
List item
Human medicine European public assessment report (EPAR): Rekambys (updated)
rilpivirine, HIV Infections
Date of authorisation: 17/12/2020,, Revision: 8, Authorised, Last updated: 05/09/2023
-
List item
Human medicine European public assessment report (EPAR): Ziextenzo (updated)
pegfilgrastim, Neutropenia
Date of authorisation: 22/11/2018,, Revision: 8, Authorised, Last updated: 05/09/2023
-
List item
Human medicine European public assessment report (EPAR): Skyrizi (updated)
Risankizumab, Psoriasis; Arthritis, Psoriatic
Date of authorisation: 26/04/2019,, Revision: 16, Authorised, Last updated: 04/09/2023
-
List item
Human medicine European public assessment report (EPAR): Bimervax (updated)
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, COVID-19 virus infection
Date of authorisation: 30/03/2023,, Revision: 2, Authorised, Last updated: 01/09/2023
-
List item
Human medicine European public assessment report (EPAR): Fintepla (updated)
Fenfluramine hydrochloride, Epilepsies, Myoclonic
Date of authorisation: 18/12/2020,, , Revision: 6, Authorised, Last updated: 01/09/2023
-
List item
Human medicine European public assessment report (EPAR): Qinlock (updated)
ripretinib, Gastrointestinal Stromal Tumors
Date of authorisation: 18/11/2021,, , Revision: 5, Authorised, Last updated: 30/08/2023
-
List item
Human medicine European public assessment report (EPAR): Bavencio (updated)
avelumab, Neuroendocrine Tumors
Date of authorisation: 18/09/2017,, Revision: 16, Authorised, Last updated: 30/08/2023
-
List item
Human medicine European public assessment report (EPAR): Zolgensma
onasemnogene abeparvovec, Muscular Atrophy, Spinal
Date of authorisation: 18/05/2020,, , , Revision: 12, Authorised, Last updated: 29/08/2023
-
List item
Human medicine European public assessment report (EPAR): Rinvoq
upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019,
, , Revision: 17, Authorised, Last updated: 29/08/2023
-
List item
Human medicine European public assessment report (EPAR): Lupkynis
Voclosporin, Lupus Nephritis
Date of authorisation: 15/09/2022,, Revision: 2, Authorised, Last updated: 29/08/2023
-
List item
Human medicine European public assessment report (EPAR): Gavreto
pralsetinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 18/11/2021,, , Revision: 6, Authorised, Last updated: 28/08/2023
-
List item
Human medicine European public assessment report (EPAR): Enjaymo
sutimlimab, Hemolysis; Anemia, Hemolytic, Autoimmune
Date of authorisation: 15/11/2022,, , Revision: 3, Authorised, Last updated: 28/08/2023
-
List item
Human medicine European public assessment report (EPAR): Reblozyl
Luspatercept, Anemia; Myelodysplastic Syndromes; beta-Thalassemia
Date of authorisation: 25/06/2020,, , Revision: 5, Authorised, Last updated: 28/08/2023
-
List item
Human medicine European public assessment report (EPAR): Cerdelga
eliglustat, Gaucher Disease
Date of authorisation: 19/01/2015,, , Revision: 16, Authorised, Last updated: 28/08/2023